Eli Lil­ly un­veils piv­otal da­ta from the star of its Der­mi­ra buy­out. But can it ri­val Dupix­ent in atopic der­mati­tis?

It’s been just over a year and a half since Eli Lil­ly shelled out $1.1 bil­lion for Der­mi­ra and its old Roche castoff le­brik­izum­ab for atopic der­mati­tis. Now the phar­ma says it has the Phase III re­sults it was look­ing for — but are they good enough to ri­val Re­gen­eron and Sanofi’s block­buster Dupix­ent?

Ac­cord­ing to topline re­sults, the IL-13 in­hibitor helped more than half of adults and ado­les­cents in two tri­als achieve at least 75% clear­ance of their eczema (mea­sured by the Eczema Area and Sever­i­ty In­dex). The stud­ies met the pri­ma­ry and key sec­ondary end­points at Week 16, Eli Lil­ly said on Mon­day, in­clud­ing skin clear­ance and itch im­prove­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.